Scarica l'app Stockscreener
74.00
0.91%
-0.7055
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EW Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$74.71
Aprire:
$74.31
Volume 24 ore:
370.62K
Relative Volume:
0.08
Capitalizzazione di mercato:
$44.06B
Reddito:
$5.72B
Utile/perdita netta:
$4.17B
Rapporto P/E:
10.62
EPS:
6.97
Flusso di cassa netto:
$490.10M
1 W Prestazione:
-2.84%
1M Prestazione:
+5.80%
6M Prestazione:
+5.62%
1 anno Prestazione:
-14.56%
Intervallo 1D:
$73.50
$74.66
Intervallo di 1 settimana:
$73.50
$76.67
Portata 52W:
$58.93
$96.12
Edwards Lifesciences Corp Stock (EW) Company Profile
Nome
Edwards Lifesciences Corp
Settore
Industria
Telefono
(949) 250-2500
Indirizzo
ONE EDWARDS WAY, IRVINE, CA
Confronta EW con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
73.98 | 44.06B | 5.72B | 4.17B | 490.10M | 6.97 |
|
ABT
Abbott Laboratories
|
134.34 | 230.98B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
105.33 | 155.49B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
385.51 | 147.45B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
89.67 | 112.85B | 33.20B | 4.26B | 5.47B | 3.29 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-30 | Aggiornamento | Stifel | Hold → Buy |
| 2025-01-16 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Downgrade | Jefferies | Buy → Hold |
| 2024-07-31 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-07-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Downgrade | TD Cowen | Buy → Hold |
| 2024-07-25 | Downgrade | Truist | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-05-14 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-02-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2023-11-28 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Iniziato | Robert W. Baird | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Overweight |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-03-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Downgrade | Bernstein | Outperform → Underperform |
| 2023-01-30 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Downgrade | Stifel | Buy → Hold |
| 2022-10-28 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Iniziato | Mizuho | Buy |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-29 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Iniziato | Truist | Buy |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-03-16 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-27 | Reiterato | Citigroup | Buy |
| 2022-01-27 | Reiterato | Evercore ISI | Outperform |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | Stifel | Buy |
| 2022-01-27 | Reiterato | UBS | Neutral |
| 2021-12-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-12-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-30 | Reiterato | Deutsche Bank | Hold |
| 2021-07-30 | Reiterato | Jefferies | Buy |
| 2021-07-30 | Reiterato | Morgan Stanley | Overweight |
| 2021-07-30 | Reiterato | Oppenheimer | Outperform |
| 2021-07-30 | Reiterato | Stifel | Buy |
| 2021-07-30 | Reiterato | UBS | Neutral |
| 2021-07-30 | Reiterato | Wells Fargo | Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-04-05 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-11 | Reiterato | Canaccord Genuity | Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Underperform |
| 2020-04-28 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Outperform |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Reiterato | Canaccord Genuity | Buy |
| 2019-09-23 | Iniziato | Piper Jaffray | Overweight |
| 2019-07-24 | Reiterato | BofA/Merrill | Buy |
| 2019-03-18 | Reiterato | Canaccord Genuity | Buy |
| 2019-01-18 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Iniziato | Deutsche Bank | Hold |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-16 | Iniziato | Barclays | Underweight |
| 2018-10-02 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Downgrade | Guggenheim | Buy → Neutral |
Mostra tutto
Edwards Lifesciences Corp Borsa (EW) Ultime notizie
Pittenger & Anderson Inc. Grows Stock Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
AlphaCentric Advisors LLC Makes New $691,000 Investment in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Baillie Gifford & Co. Buys 498,100 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Kentucky Retirement Systems Insurance Trust Fund Has $287,000 Stock Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Ownership Capital B.V. Sells 200,754 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) Position Lessened by Chevy Chase Trust Holdings LLC - MarketBeat
CIBC Asset Management Inc Sells 31,973 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Rhumbline Advisers Sells 37,002 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
WD Rutherford LLC Cuts Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) Holdings Raised by Empower Advisory Group LLC - MarketBeat
First Merchants Corp Has $773,000 Stock Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Leavell Investment Management Inc. Sells 6,450 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Peering Into Edwards Lifesciences's Recent Short Interest - Benzinga
Edwards Lifesciences Co. (NYSE:EW) Director Steven R. Loranger Sells 5,739 Shares - MarketBeat
Vontobel Holding Ltd. Cuts Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences (NYSE:EW) Stock Rating Lowered by Wolfe Research - MarketBeat
Edwards Lifesciences (NYSE:EW) Price Target Raised to $75.00 - MarketBeat
Scott B. Ullem Sells 11,250 Shares of Edwards Lifesciences Co. (NYSE:EW) Stock - MarketBeat
Edwards Lifesciences' SWOT analysis: stock faces TAVR headwinds, TMTT potential - Investing.com
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MSN
FY2025 EPS Forecast for Edwards Lifesciences Cut by Analyst - MarketBeat
Capital Advisors Inc. OK Decreases Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences (NYSE:EW) Shares Gap Up After Strong Earnings - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Savant Capital LLC - MarketBeat
New York State Teachers Retirement System Sells 42,203 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
26,922 Shares in Edwards Lifesciences Co. (NYSE:EW) Acquired by Asset Planning Inc - MarketBeat
Edwards Lifesciences (NYSE:EW) Price Target Raised to $71.00 at Canaccord Genuity Group - MarketBeat
Edwards Lifesciences (NYSE:EW) Issues FY 2025 Earnings Guidance - MarketBeat
Edwards Lifesciences (NYSE:EW) Releases Q1 2025 Earnings Guidance - MarketBeat
Van ECK Associates Corp Has $12.67 Million Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Morgan Stanley Issues Positive Forecast for Edwards Lifesciences (NYSE:EW) Stock Price - MarketBeat
Edwards Lifesciences (NYSE:EW) Price Target Cut to $73.00 by Analysts at Evercore ISI - MarketBeat
Piper Sandler Increases Edwards Lifesciences (NYSE:EW) Price Target to $73.00 - MarketBeat
Edwards Lifesciences Corporation (NYSE:EW) Q4 2024 Earnings Call Transcript - MSN
Edwards Lifesciences (NYSE:EW) Issues Earnings Results - MarketBeat
AustralianSuper Pty Ltd Has $197.57 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Bogart Wealth LLC Increases Stock Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. Sells 6,500 Shares - MarketBeat
Edwards Lifesciences Director Sells Shares - TradingView
Barclays Increases Edwards Lifesciences (NYSE:EW) Price Target to $90.00 - MarketBeat
Insider Unloading: LESLIE HEISZ STONE Sells Options, Realizes $179K - Benzinga
Ingalls & Snyder LLC Sells 3,463 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Entropy Technologies LP Sells 17,004 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Executives at Edwards Lifesciences Corp Execute Stock Transactions - TradingView
Earnings call transcript: Edwards Lifesciences Q4 2024 beats estimates, stock surges - MSN
Daiwa Adjusts Price Target on Edwards Lifesciences to $77 From $72, Maintains Neutral Rating - Marketscreener.com
Royal Bank of Canada Reaffirms Outperform Rating for Edwards Lifesciences (NYSE:EW) - MarketBeat
Edwards Lifesciences Corp Azioni (EW) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.99%
0.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):